Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.265    -0.005 (-1.85%)
Bid:
0.25
Ask:
0.28
Spread: 0.03 (12.00%)
Market Cap: £15.36m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Pre-close trading update

7 Jul 2022 07:00

RNS Number : 6522R
CAP-XX Limited
07 July 2022
 

 

7 July 2022

CAP-XX Limited

("CAP-XX" or "the Company")

Pre-close trading update

 

CAP-XX Limited, a world leader in the design and manufacture of thin, prismatic supercapacitors and energy management systems, announces a trading update in respect of the financial year ended 30 June 2022.

The Company is pleased to announce that revenues and adjusted EBITDA* for the year ended 30 June 2022 are, subject to clearance by CAP-XX's independent auditors, expected to be in line with current market expectations. Product sales are up 39% by value on the previous year and total revenue up 31% on the previous year at A$5.6m. Adjusted EBITDA* is expected to be a loss of (A$699K), after excluding A$2.4m in legal fees associated with the AVX and Maxwell court cases. EBITDA for FY22 is expected to be a loss of (A$3.1m) when the A$2.4m in legal fees are included.

Both court cases are progressing favourably and the Board, under advice from our lawyers, remains confident of the Company's prospects of securing a favourable outcome. This has enabled the Board to secure litigation funding which is expected to be in place to cover the legal fees in FY23. Legal fees associated with these cases in FY22 were approximately A$2.0m higher than previously forecast as the cases moved closer to resolution and legal fees were incurred sooner than expected.

The Board is encouraged by the outlook for FY23 and beyond and expects to see continued strong growth in product sales. This growth is being driven by increasing customer demand for DMF and DMT products, cylindrical supercapacitors and traditional supercapacitor products made in Malaysia. In addition new products, such as LICs together with the expansion of our distribution channels are expected to increase sales. Commissioning of the DMH line is expected to be completed around the middle of 2023, as time and resources allow, and subject to customer demand.

Cash reserves as at the end of June 2022 were approximately A$1.6m

The Company's results for the year ended 30 June 2022 are expected to be released on 29 September 2022.

* Adjusted EBITDA excludes the Company's legal expenses associated with its patent infringement actions.

 

 

For further information contact:

CAP-XX Limited

Anthony Kongats (CEO)

 

+61 (0) 2 9428 0139

Kreab (Financial PR)

Robert Speed

 

+44 (0) 20 7074 1800

Allenby Capital (Nominated Adviser and Joint Broker)

David Hart / Alex Brearley (Corporate Finance)

Tony Quirke (Sales and Corporate Broking)

 

+44 (0) 20 3328 5656

Cenkos Securities plc (Joint Broker)

Neil McDonald / Pete Lynch

 

+44 (0) 13 1220 6939

 

More information is available at www.cap-xx.com

 

Notes to Editors:

 

CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and to an increasing extent, in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUBPMUPPUCM
Date   Source Headline
31st Oct 20244:35 pmRNSProposed Fundraising
21st Oct 20249:57 amRNSUpdate re. final results and current trading
16th Oct 20247:00 amRNSContract Win
5th Sep 20247:00 amRNSTrading Update and Notice of Results
30th Aug 20245:00 pmRNSTotal Voting Rights
14th Aug 20247:12 amRNSGrant of options
6th Aug 20249:18 amRNSHolding(s) in Company
5th Aug 20247:00 amRNSExercise of warrants and total voting rights
29th Jul 20247:00 amRNSHolding(s) in Company
16th Jul 20247:00 amRNSMOU to establish technology partnership
18th Jun 20247:00 amRNSBoard Changes and Grant of Share Options
20th May 20247:00 amRNSHolding(s) in Company
13th May 20247:00 amRNSHolding(s) in Company
7th May 202410:10 amRNSHolding(s) in Company
7th May 20247:00 amRNSTrading Update
1st May 202411:08 amRNSHolding(s) in Company
30th Apr 20245:00 pmRNSTotal Voting Rights
25th Apr 20249:24 amRNSHolding(s) in Company
24th Apr 20245:04 pmRNSN05/24 - CAP-XX Limited - Restoration of trading
23rd Apr 20248:36 amRNSResult of General Meeting
8th Apr 20249:12 amRNSLitigation with Kyocera AVX settled
28th Mar 20245:00 pmRNSTotal Voting Rights
27th Mar 20248:22 amRNSSuspension of trading
27th Mar 20247:29 amRNSN04/24 - CAP-XX Limited - Suspension of trading
25th Mar 20247:00 amRNSResult of Retail Offer and Total Voting Rights
22nd Mar 20247:00 amRNSResult of Placing and Notice of General Meeting
21st Mar 20244:40 pmRNSREX Retail Offer
21st Mar 20244:35 pmRNSProposed Placing and Subscription to raise £2.0m
21st Mar 20249:00 amRNSLitigation Settlement Agreement with Tesla, Inc
19th Mar 202412:31 pmRNSHolding(s) in Company
18th Mar 20242:56 pmRNSHolding(s) in Company
15th Mar 202412:50 pmRNSHolding(s) in Company
15th Mar 20247:07 amRNSHolding(s) in Company
14th Mar 20247:00 amRNSUpdate on litigation
13th Mar 20247:00 amRNSCorporate Update
12th Mar 20247:00 amRNSRetirement of CFO
28th Feb 20247:00 amRNSUpdate on litigation and trading
19th Feb 20247:00 amRNSCessation of appeals process
1st Feb 20247:00 amRNSInterim Results
29th Jan 20247:00 amRNSUpdate on Patent Infringement
22nd Jan 202412:57 pmRNSChange of Joint Broker
10th Jan 20247:02 amRNSUpdate on IP and appeals process
29th Dec 20231:00 pmRNSTotal Voting Rights
21st Dec 20237:00 amRNSTrading Update
18th Dec 20237:00 amRNSUpdate on Patent Infringement
7th Dec 20237:00 amRNSCAP-XX finalises two new patents
5th Dec 20237:00 amRNSIssue of Shares and Director/PDMR Shareholdings
1st Dec 20237:00 amRNSUpdate re. R&D rebate and other matters
29th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 202311:29 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.